Cardiovascular late effects and the ongoing care of adult cancer survivors

Disease Management

Volumn 11, Issue 1, 2008, Pages 1-6

  Carver, Joseph R ^a   Ng, Andrea ^b   Meadows, Anna T ^c   Vaughn, David J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; EPIRUBICIN; MITOXANTRONE; PLATINUM; TRASTUZUMAB;

CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVOR; CARDIOTOXICITY; CARDIOVASCULAR EFFECT; CLINICAL FEATURE; DISEASE COURSE; DOSE RESPONSE; ELDERLY CARE; HUMAN; NOTE; RADIATION DOSE; SURVIVAL TIME; TESTIS CANCER; VASCULAR DISEASE;

ADULT; CARDIOVASCULAR DISEASES; HUMANS; INCIDENCE; NEOPLASMS; SURVIVAL RATE; TIME FACTORS; UNITED STATES;

EID: 39449134239     PISSN: 1093507X     EISSN: None     Source Type: Journal    
DOI: 10.1089/dis.2008.111714     Document Type: Note

References (29)

1. Institute of Medicine and National Research Council, Committee on Cancer Survivorship: Improving Care and Quality of Life, National Cancer Policy Board. From Cancer Patient to Cancer Survivor: Lost in Transition. Washington, DC: National Academies Press; 2005.
2. Welch HG, Schwartz LM, Woloshin S. Are increasing 5-year survival rates evidence of success against cancer? JAMA. 2000;283:2975-2978.
3. Ries LAG, Eisner MP, Kosary CL, et al, eds. SEER Cancer Statistics Review, 1975-2002. Bethesda, MD: National Cancer Institute; 2005. Available at: 〈seer.cancer.gov/csr/1975_2002〉. Accessed December 17, 2007.
4. Travis LB, Rabkin CS, Morris Brown L, et al. Cancer survivorship: genetic susceptibility and second primary cancers: research strategies and recommendations. J Natl Cancer Inst. 2006;98:15-25.
5. Hewitt M, Weiner SL, Simone, JV, eds. Childhood Cancer Survivorship: Improving Care and Quality of Life. Washington, DC: National Academics Press; 2003.
6. Oeffinger KC, Mertens AC, Sklar CA, et al. Chronic health conditions in adult survivors of childhood cancer. N Eng J Med. 2006;355:1572-1582.
7. Steinherz LJ, Steinherz PG, Tan CT, et al. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA. 1991;266:1672-1677.
8. Lipshultz SE, Colan SD, Gelber RD, et al. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med. 1991;324:808-815.
9. Pein F, Sakiroglu O, Dahan M, et al. Cardiac abnormalities 15 years and more after adriamycin therapy in 229 childhood survivors of a solid tumour at the Institut Gustave Roussy. Br J Cancer. 2004;91:37-44.
10. Oeffinger KC, Hudson MM. Long-term complications following childhood and adolescent cancer: foundations for providing risk-based health care for survivors. CA Cancer J Clin. 2004;54:208-236.
11. Kremer LC, van Dalen EC, Offringa M, et al. Anthracycline-induced clinical heart failure in a cohort of 607 children: long-term follow-up study. J Clin Oncol. 2001;19:191-196.
12. Hequet O, Le QH, Moullet I, et al. Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults. J Clin Oncol. 2004;22:1864-1871.
13. Bonneterre J, Roche H, Kerbrat P, et al. Long-term cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French adjuvant study group. J Clin Oncol. 2004;22:3070-3079.
14. Kremer LC, van der Pal HJ, Offringa M, et al. Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review. Ann Oncol. 2002;13:819-829.
15. Heidenreich PA, Hancock SL, Lee BK, et al. Asymptomatic cardiac disease following mediastinal irradiation. J Am Coll Cardiol. 2003;42:743-749.
16. Heidenreich PA, Hancock SL, Vagelos RH, et al. Diastolic dysfunction after mediastinal irradiation. Am Heart J. 2005;150:977-982.
17. Heidenreich PA, Schmittger I, Strauss HW, et al. Screening for coronary artery disease after mediastinal irradiation for Hodgkin's disease. J Clin Oncol. 2007;25:43-49.
18. Lee CK, Aeppli D, Nierengarten ME. The need for long-term surveillance for patients treated with curative radiotherapy for Hodgkin's disease: University of Minnesota experience. Int J Radiat Oncol Biol Phys. 2000;48:169-179.
19. Reinders JG, Heijmen BJ, Olofsen-van Acht MJ, et al. Ischemic heart disease after mantlefield irradiation for Hodgkin's disease in long-term follow-up. Radiother Oncol. 1999;51:35-42.
20. Adams MJ, Lipsitz SR, Colan SD, et al. Cardiovascular status in long-term survivors of Hodgkin's disease treated with chest radiotherapy. J Clin Oncol. 2004;22:3139-3148.
21. Adams MJ, Lipshultz SE, Schwartz C, et al. Radiation-associated cardiovascular disease: manifestations and management. Semin Radiat Oncol. 2003;13:346-356.
22. Carver JR, Shapiro CE, Ng A, Vaughn DJ. American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiopulmonary late effects. J Clin Oncology. 2007;25:3991-4008.
23. Landier W, Bhatia S, Eshelman DA, et al. Development of risk-based guidelines for pediatric cancer survivors: the Children's Oncology Group Long-Term Follow-Up Guidelines from the Children's Oncology Group Late Effects Committee and Nursing Discipline. J Clin Oncol. 2004;22:4979-4990.
24. Scottish Intercollegiate Guidelines Network. 76: Long term follow up of survivors of childhood cancer: A national clinical guideline. 2004. Date last modified: July 3, 2005. Available at: 〈www.sign.ac.uk/guidelines/fulltext/ 76/index.html〉. Accessed December 17, 2007.
25. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation. 2005;112:e154-e235.
26. Executive summary: HFSA 2006 Comprehensive Heart Failure Practice Guideline. J Card Fail. 2006;12:10-38.
27. Smith SC, Jr., Greenland P, Grundy SM. AHA Conference Proceedings. Prevention conference V: Beyond secondary prevention: Identifying the high-risk patient for primary prevention: executive summary. American Heart Association. Circulation. 2000;101:111-116.
28. Lipshultz SE, Lipsitz SR, Sallan SE, et al. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol. 2005;23:2629-2636.
29. Guldner L, Haddy N, Pein F, et al. Radiation dose and long term risk of cardiac pathology following radiotherapy and anthrcyclin for a childhood cancer. Radiother Oncol. 2006;81:47-56.